ROCKWELL MEDICAL

Targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

January 2017

Safe Harbor Statement

This presentation contains forward-looking statements. All statements, other than statements of historical facts, including, among others, statements regarding the Company's future plans, products (investigational or otherwise), financial position, business strategy, projected levels of growth, projected costs and projected financing needs, projected roll-out or approval dates, are forward-looking statements. Those statements include statements regarding the intent, belief or current expectations of Rockwell Medical and members of the Company's management team, as well as the assumptions on which such statements are based, and generally are identified by the use of words such as "may," "will," "seeks," "anticipates," "forecast," "upcoming," "believes," "estimates," "expects," "plans," "intends," "should", "potential" or similar expressions. Forward looking statements are not guarantees of future performance and involve risks and uncertainties, including those set forth in the Company's annual and quarterly reports filed with the SEC. Actual results may differ materially from those contemplated by such forward-looking statements.

The Company believes these forward-looking statements are reasonable. However, undue reliance should not be placed on any forward-looking statements, which are based on current expectations. All written and oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by these cautionary statements. Further, forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time unless required by law.

Company Overview

- Corporate offices located in Wixom, Michigan USA
- 4 Manufacturing facilities (MI, TX, SC, IA)
- Approximately 330 employees
- We are committed to bringing new innovative therapies to the market to improve the lives of patients
  - Triferic® – revolutionary iron replacement hemoglobin maintenance therapy
  - Calcitriol – generic vitamin D injection (packaged in vial)
  - CitraPure® – innovative dialysate lowers inflammation and cost

Leader in Manufacturing and Delivering Innovative Dialysis Products

Triferic® – Innovative Iron Replacement Therapy for Dialysis Patients ○ The only FDA approved product indicated to replace iron and maintain hemoglobin in hemodialysis patients ○ Novel iron molecule binds directly to transferrin	Approx. $300M US market; $1B global
Calcitriol – Preparing to Launch FDA Approved Generic Drug ○ Original most potent lowest dose vitamin D injection ○ Lower cost pure play for current US market Vitamin D Analogs	Approx. $250M US Market
Growing Concentrate Business ○ Strong, existing customer relationships with standard-of-care products ○ One of two major concentrate suppliers in the US	Revenue: $50M cash flow positive
Experienced, Proven Management Team ○ Successful with multiple product launches, product development, clinical development, marketing and sales	

Experienced Management Team

Robert L. Chioini
Founder, Chairman and CEO

Thomas E. Klema
VP, CFO and Secretary

Ajay Gupta, M.D.
Chief Scientific Officer

Raymond D. Pratt, M.D.
Chief Medical Officer

Product Development & Acquisitions

- Strategic product acquisitions and successful product launches in the dialysis space
  - Dri-Sate®, SteriLyte®, Renal Pure® and CitraPure® all developed in-house and have become the standard-of-care in the hemodialysis concentrate market
  - Triferic® and Calcitriol acquired; both offer clinical and cost benefit and positioned for success

Clinical Development & Launch Success

- Successfully completed clinical development of Triferic® with execution of large-scale clinical studies over 10 years
- Successfully launched multiple, industry-changing dialysis products over 20 years

Marketing & Sales

- Created solid brand recognition with innovative standard-of-care products
- Developed loyal customer base and strong customer relationships
- Built $50M+ operating business from the ground up

Innovative, Cost Saving Products for Dialysis Patients in the Renal Space

Drug Products

Triferic®

- Replaces the iron loss that occurs to patients “real-time” during dialysis treatment session
- Delivered via dialysate saves significant nursing time
- Iron binds directly to transferrin and is transported to bone marrow for Hgb incorporation; no increase in iron stores
- Proven safety data: 100,000 human doses, no anaphylaxis
- ESA sparing study (PRIME) showed Triferic® reduces ESA use 35% overall and 74.4% in hypo-responders
- U.S. Commercial launch underway – Blockbuster Potential

Calcitriol

- Original, most potent active vitamin-D injection
- Only Calcitriol injection available in vials
- Clinically equivalent in safety and efficacy to the two branded drugs
- Lower cost alternative
- FDA Approved, preparing for commercial launch

Concentrate Products

CitraPure® Citric-Acid Concentrate

Renal Pure® Liquid Acid Concentrate

RenalPure® Powder Bicarbonate Concentrate

Dri-Sate® Dry Acid/Mixing System

SteriLyte® Liquid Bicarbonate Concentrate

Ancillary Products

Triferic® - Revolutionary Iron Replacement; Key Growth Driver

Overcomes High-Ferritin, High-Infection and Functional Iron Deficiency (FID) in HD Patients

- **FDA Indicated for iron maintenance therapy**
- **Small 5-7 mg iron dose over 4 hours**
- **Iron binds completely to transferrin**
- **Consistently maintains hemoglobin**
- **No iron trapped in the liver**
- **No increase in ferritin (iron stores)**
- **No increase in inflammation**
- **No increase in infections (vs placebo)**
- **No anaphylaxis (vs placebo)**
- **Decrease in blood transfusions (vs placebo)**

Product Pipeline



Global Sales Initiative

- **License Triferic® outside U.S. for HD with key partners world-wide – $1B+ market opportunity; China and Middle East secured**
- **License Triferic® worldwide for other clinical indications PD, TPN, Cancer and IRIDA (orphan); China secured**

We Expect Triferic® to Become the Global Standard of Care for HD Patients


ROCKWELL
MEDICAL